Sotrastaurin

For research use only. Not for use in humans.

目录号:S2791 别名: AEB071

Sotrastaurin Chemical Structure

Molecular Weight(MW): 438.48

Sotrastaurin是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1566.89 现货
RMB 1414.55 现货
RMB 5468.97 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Sotrastaurin发表文献32篇:

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Sotrastaurin是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。
特性 同以往的PKC抑制剂不同,AEB071并不会在激活诱导的细胞死亡模型中增强鼠T细胞原幼细胞的凋亡。
靶点
PKCθ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCα [1]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCδ [1]
(Cell-free assay)
0.22 nM(Ki) 0.64 nM(Ki) 0.95 nM(Ki) 1.8 nM(Ki) 2.1 nM(Ki)
体外研究

在人和鼠的早期T细胞中,毫微摩尔级浓度的AEB071 (< 10μM)则能有效消除早期T细胞激活的信号如白介素-2分泌物和CD25表达。在没发生非特异性抗增殖的效应的细胞中,AEB071 (200 nM)能抑制CD3/CD28抗体和同种抗原诱导的T瞎报增殖反应。AEB071(<3 μM)可以显著抑制淋巴细胞功能相关抗原1介导的T细胞的粘附作用。[1] AEB071(< 20 μM)特异性地降低CD79突变体ABC DLBCL细胞系的增殖,随之能减少NF-κB信号活性。3 μM 浓度的AEB071可诱导CD79突变细胞在G1阻断和/或细胞坏死。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cell NVvpNVlETnWwY4Tpc44hSXO|YYm= M3jJZVExOCCwTR?= MV6zJIg> NVnJVIhtTE2VTx?= NX;rWFY2cW6qaXLpeJMhelKQQTDzfY51cGW|aYO= MmPrNlU3QTFzNUi=
HUVECs  MYfGeY5kfGmxbjDBd5NigQ>? MW[1NFBvVQ>? NGLiTooyKGh? MV3S[YR2[2W|IFTUXE1VemmpZ3Xy[YQhTW6mb4To[Yxq[WxiRInz[pVv[3Srb36= NFrNSoYzPTZ|NEWzPC=>
A549 NFnSdItHfW6ldHnvckBCe3OjeR?= NYTHcppPOC5zwrFOwG0> Mn6wNlQhcA>? NUG0cI45\GWlcnXhd4V{KHSqZTDy[YxifGm4ZTDQT2Mu|rFibHX2[Ywhd25iY3XscEBu\W2kcnHu[UBkd3S{ZXH0[YQhSVNvSW[= NH:1WpUzPTJzOEG2NS=>
A549 NVr2bYM1TnWwY4Tpc44hSXO|YYm= NFnXZWgxNjIEoN88US=> MV:yOEBp MXjy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUmgZY5lKGmwdHXndolvKM7{MR?= MVyyOVIyQDF4MR?=
A549 NHfZXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[wMlHDqM7:TR?= M3\ETVI1KGh? NWjpS|Fq\W6qYX7j[ZMh\3Kxd4ToJIlvcGmkaYTpc44h[2:2cnXheIVlKHerdHigRXMuUVZ? M{fYVVI2OjF6MU[x
Mel202 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlUh|ryP NFXvdJE{KGh? MnfTSG1UVw>? MkK0[Y5p[W6lZYOgTXIucW6mdXPl[EBz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJk> M3:5b|I1PTl3M{i1
92.1 M3;Ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTvb|kxNjVizszN M1jIdFMhcA>? NVqwcHpoTE2VTx?= NXzlZ|Zb\W6qYX7j[ZMhUVJvaX7keYNm\CC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHl? NEjnbm8zPDV7NUO4OS=>
OCM3 MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTBb4kxNjVizszN MXqzJIg> NEjYSYtFVVOR NVrPeYxU\W6qYX7j[ZMhUVJvaX7keYNm\CC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHl? M2D5W|I1PTl3M{i1
Mel202 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOxNE42KM7:TR?= NVPUOoptOyCq M1n0SmROW09? NXvtOI1wcW6lcnXhd4V{KEmULXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3UEoB?= NVLKbWhlOjR3OUWzPFU>
92.1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HMZlAvPSEQvF2= NWryU2ZROyCq NF:zdJVFVVOR MonEbY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? MnXmNlQ2QTV|OEW=
OCM3 M17xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGxfJBYOC53IN88US=> Mle2N{Bp NVn4N5BITE2VTx?= MlrFbY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? MUeyOFU6PTN6NR?=
Jeko-1 NXPFTZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHTlYzOC12IN88US=> MUjEUXNQ NF7OfXlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MUKyOFM3Ojl|NR?=
Mino M{\nfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;MdVUxNTRizszN MV\EUXNQ M12x[olvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFzI[3IzPDN4MkmzOS=>
Rec-1 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWwNE01KM7:TR?= M2e2U2ROW09? M3LKfolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3;HbFI1OzZ{OUO1
SP49 NGfiWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2wMVQh|ryP M2fRS2ROW09? NXuwfYxYcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NYnIXXJsOjR|NkK5N|U>
Jeko-1 MWXGeY5kfGmxbjDBd5NigQ>? MXuyMlUh|ryPwrC= MXixNkBp MVvEUXNQ MVfkc5dvemWpdXzheIV{KE6ILd86RkB1[XKpZYSg[4Vv\XN? M{fnfVI1OzZ{OUO1
Mino M1PweWZ2dmO2aX;uJGF{e2G7 MnjwNk42KM7:TdMg Ml:0NVIhcA>? MVnEUXNQ MmDx[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| MljLNlQ{PjJ7M{W=
Rec-1 M{LJOWZ2dmO2aX;uJGF{e2G7 MmC4Nk42KM7:TdMg M{fZPVEzKGh? M4r0XWROW09? MkX2[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| NVG5dXJIOjR|NkK5N|U>
SP49 M4r4fGZ2dmO2aX;uJGF{e2G7 NWflW5JMOi53IN88UeKh MlHhNVIhcA>? M3PHO2ROW09? M{S3ZoRwf26{ZXf1cIF1\XNiTl[t{tpDKHSjcnfleEBo\W6ncx?= NIi3e4ozPDN4MkmzOS=>
CD3+ T  MXPGeY5kfGmxbjDBd5NigQ>? MXSwMVUxOCCwTR?= MnrnNUBp NHzIc4lqdmirYnn0d{BPTi4QulKgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnGzNlM2PzN{OEO=
Mel202 M1XFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiwMVUh|ryP Ml6wO|IhcA>? NVnyVWdqTE2VTx?= MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWT2N|ZQOjJ4NUO5Olg>
Omm1.3 NWLhZlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPRe5AxNTVizszN NXTCXIlEPzJiaB?= Mn\DSG1UVw>? NXy2PFl1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MnLqNlI3PTN7Nki=
92.1 NUSxRnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMVUh|ryP MVq3NkBp NHfLWIxFVVOR MkfYbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MVyyNlY2Ozl4OB?=
Mel202 M1TtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG1JO69VQ>? NH\aO24zPCCq MlLRSG1UVw>? M4PObolv\HWlZYOgS|Eh[XK{ZYP0xsA> NHfyflMzOjZ3M{m2PC=>
Omm1.3 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW1JO69VQ>? M2TOVlI1KGh? MmnzSG1UVw>? NHewXWhqdmS3Y3XzJGcyKGG{cnXzeOKh MnLpNlI3PTN7Nki=
92.1 NFT1WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYOGRCPSEQvF2= MlH6NlQhcA>? NE\4WHhFVVOR M3XVeolv\HWlZYOgS|Eh[XK{ZYP0xsA> MUeyNlY2Ozl4OB?=
Mel202 NWXLNVdqSXCxcITvd4l{KEG|c3H5 NHzFSos2KM7:TR?= M3Kw[VczKGh? M1LKU2ROW09? NHPtW|ZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MlHsNlI3PTN7Nki=
Omm1.3 MWPBdI9xfG:|aYOgRZN{[Xl? M3LCOFUh|ryP NV\nWYdQPzJiaB?= MkLSSG1UVw>? NHr3RmZqdmS3Y3XzJIFxd3C2b4Ppdy=> MUSyNlY2Ozl4OB?=
92.1 NGHIOnFCeG:ydH;zbZMhSXO|YYm= NVy4c5BTPSEQvF2= MXy3NkBp MUfEUXNQ MWDpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[lYX70cJk> M1rIeFIzPjV|OU[4
Mel202 Mk\rSpVv[3Srb36gRZN{[Xl? M2LCU|Uh|ryP MXyyOEBp MX3pcohq[mm2czDlfJBz\XO|aX;uJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiUFvDJIl{d2[xcn3z MUOyNlY2Ozl4OB?=
Omm1.3 NUH3OYc5TnWwY4Tpc44hSXO|YYm= NUWw[4xQPSEQvF2= MoDjNlQhcA>? NEPwO5lqdmirYnn0d{BmgHC{ZYPzbY9vKGGwZDDwbI9{eGixconsZZRqd25ib3[gVGtEKGm|b3\vdo1{ M1;6WlIzPjV|OU[4
92.1 NWjZXVBKTnWwY4Tpc44hSXO|YYm= Ml\BOUDPxE1? NEG0OoozPCCq MoD1bY5pcWKrdIOg[ZhxemW|c3nvckBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIGDLR{Bqe2:ob4Ltdy=> MYmyNlY2Ozl4OB?=
HBL1 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW2NE4yPi1{MDFOwG0> NGr1VYU2KGR? NU\zWXRNUUN3ME2wMlUh|ryP MlP6NlE{OjR7MkC=
TMD8 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[z[GExNjF4LUKwJO69VQ>? M3L2V|Uh\A>? MmeyTWM2OD1yLkKg{txO NGrYfWYzOTN{NEmyNC=>
OCI-Ly10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5fW0xNjF4LUKwJO69VQ>? NU\6ZXFEPSCm NHP2SZlKSzVyPUGuN{DPxE1? NEfFcmYzOTN{NEmyNC=>
U2932 NHjaWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfwdGcxNjF4LUKwJO69VQ>? MojXOUBl Ml;FTWM2OD1zMDFOwG0> MWWyNVMzPDl{MB?=
OCI-Ly3 NUP5VJhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLX[pl[OC5zNj2yNEDPxE1? NGrGd2U2KGR? MnzzTWM2OO,:nkKwJO69VQ>? MnPCNlE{OjR7MkC=
SuDHL2 NGjaNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezNFl{OC5zNj2yNEDPxE1? MWi1JIQ> NH;4fYJKSzVy78{eNlAh|ryP MoDsNlE{OjR7MkC=
SuDHL4 M3PhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVVoMxNjF4LUKwJO69VQ>? M4DBNVUh\A>? MkH4TWM2OO,:nkKwJO69VQ>? MnvyNlE{OjR7MkC=
DB M2LRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PiTlAvOTZvMkCg{txO M3PQPFUh\A>? MYPJR|Ux97zgMkCg{txO NGrlU|QzOTN{NEmyNC=>
Jurkat IL-2 NXW3cJo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3uW3pyUUN3ME22MlcyKMLzIEOuO|Yh|ryP NITMV2kyQTl2MEK1PS=>
PBMC IL-2 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrTTWM2OD12Lki0JOKyKDFwN{CgJO69VQ>? NFLzTHQyQTl2MEK1PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pPKCδ/θ / phosphorylated MARCKS / p53 / MDM2 / PUMA / p21; 

PubMed: 29593251     


Cell lines OMM2.3, OMM2.5 and OMM1 were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM Nutlin-3 and 1 µM Sotrastaurin, and cell lines MEL202, MEL270 and MM66 with 2䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ€𢡄뙤ෆ€䀷痗뙤ෆ౴뙤ෆ㵶痗뙤ෆ뺖᎒泌Itemセ᎒Count﫨呂뚔ෆ猴፲뙤ෆ፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄堚Ѽ齃礤v�堞ﻮ᎒猢Wセ᎒䨼Ą鹿齃

Cyclin D1 / p27(Kip1) ; 

PubMed: 22653968     


AEB071 selectively increased p27 and decreased cyclin D1 expression in GNAQ mutant UM cells. Cells were treated with 0, 2, or 5 μM AEB071 for 72 hours and analyzed by immunoblot. WT = GNAQ wild type; MT = GNAQ mutation.

Bcl-xl / XIAP / Survivin ; 

PubMed: 22653968     


AEB071 decreased the expression of antiapoptotic proteins Bcl-xL, XIAP, and survivin in GNAQ mutated cells. WT = GNAQ wild type; MT = GNAQ mutation.

PKCα / PKCδ / PKCβ / PKCε / PKCθ ; 

PubMed: 22653968     


AEB071 inhibited PKC expression in UM cells. Cells were treated with 5 μM AEB071 for 24 hours in the presence of 10% FBS and subjected to immunoblot analysis. PKCδ, ε and θ levels in AEB treated cells relative to control (DMSO treated) cells are also show䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨Ղà㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ猴፲사Ղ፲씢痗猸፲髸莤䥷堙᎒

p-Marcks / p-ERK / p-AKT / p-S6 / Marcks / ERK / AKT / S6; 

PubMed: 22653968     


AEB071 inhibits PKC and mTOR pathways but not AKT. Western Blot of MARCKS, ERK, ribosomal S6 and AKT phosphorylation following drug treatments for 24 hrs. α-Tubulin was used as a loading control.

29593251 22653968
Growth inhibition assay
Cell viability ; 

PubMed: 22653968     


AEB071 selectively reduced viability of UM cells harboring GNAQ mutations. Cells were treated with varying amount of AEB071 for 72 hours. Data are presented as mean±SD of 4 or 5 independent experiments. NM = normal melanocytes; WT = GNAQ wild type; MT = G䲧疝Ỵ疞㧀疜膉

22653968
体内研究 AEB071(80 mg/kg) 可以在体内显著抑制SCID的皮下TMD8移植模型肿瘤的生长。[2] 每日两次口服10 mg/kg 和30 mg/kg AEB071,能延长心脏移植的大鼠的存活率,这种作用是剂量依赖抑制免疫力的效应。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[3]
- 合并
  • Animal Models: 雄性 Wistar/F大鼠
  • Dosages: 10 mg/kg 和 30 mg/kg
  • Administration: 口服一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.41 mM)
Ethanol 2 mg/mL (4.56 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 438.48
化学式

C25H22N6O2

CAS号 425637-18-9
储存条件 粉状
溶于溶剂
别名 AEB071

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02273219 Active not recruiting Drug: AEB071|Drug: BYL719 Uveal Melanoma Richard D. Carvajal|Columbia University November 2014 Phase 1
NCT01801358 Terminated Drug: AEB071|Drug: MEK162 Uveal Melanoma Array BioPharma August 2013 Phase 1|Phase 2
NCT01430416 Completed Drug: AEB071 Uveal Melanoma Novartis Pharmaceuticals|Novartis December 20 2011 Phase 1
NCT01402440 Terminated Drug: AEB071 Diffuse Large B-Cell Lymphoma Novartis Pharmaceuticals|Novartis November 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you give me the information about how to prepare Sotrastaurin for oral administration in mice?

  • 回答:

    S2791 Sotrastaurin can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution which can be used for injection, and in 2% DMSO/corn oil at 10 mg/ml as a suspension for oral administration.

PKC Signaling Pathway Map

PKC Inhibitors with Unique Features

相关PKC产品

Tags: 购买Sotrastaurin | Sotrastaurin供应商 | 采购Sotrastaurin | Sotrastaurin价格 | Sotrastaurin生产 | 订购Sotrastaurin | Sotrastaurin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID